MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Himmelreich Jeffrey C

Role Head of Finance

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	30,000	$0.00	--

Holdings After Transaction: Stock Options — 30,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 30,000 options Exercise price: $1.28 per share Expiration date: April 10, 2036 +4 more

7 metrics

Options granted 30,000 options Stock options for common stock granted April 10, 2026

Exercise price $1.28 per share Conversion or exercise price of granted stock options

Expiration date April 10, 2036 Expiration of the granted stock options

Underlying shares 30,000 shares Common shares underlying the granted options

Post-grant option holdings 30,000 options Total options held following this transaction

Initial vesting 25% at first anniversary Portion of options vesting one year after April 10, 2026 grant date

Ongoing vesting Remaining over 36 months Options vest monthly after first anniversary for three years

Key Terms

Stock Options, 2021 Equity Incentive Plan, vesting schedule, underlying security

4 terms

Stock Options financial

"The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

vesting schedule financial

"vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

underlying security financial

"underlying_security_title: "Common Stock", underlying_security_shares: "30000.0000""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Himmelreich Jeffrey C

(Last) (First) (Middle)

50 CARLAND DRIVE

(Street)

ARDEN NORTH CAROLINA 28704-8836

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.28	04/10/2026		A		30,000		04/10/2027(1)	04/10/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	Jeffrey Himmelreich	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA (MAIA) report for Jeffrey C. Himmelreich?

MAIA reported a compensation grant to Head of Finance Jeffrey C. Himmelreich of stock options for 30,000 shares of common stock. These options are not an open-market purchase but an award under the company’s 2021 Equity Incentive Plan.

What is the exercise price and size of the MAIA stock options granted?

The grant consists of stock options for 30,000 shares of MAIA common stock with an exercise price of $1.28 per share. This price is the cost Himmelreich must pay per share if he chooses to exercise the options.

How do the MAIA stock options granted to Himmelreich vest over time?

The options vest on a four-year schedule. 25% of the 30,000 options vest on the first anniversary of the April 10, 2026 grant date, and the remaining options vest ratably monthly over the following 36 months, encouraging long-term service.

When do the newly granted MAIA stock options expire?

The stock options granted to Jeffrey C. Himmelreich expire on April 10, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to buy MAIA common shares at the $1.28 exercise price.

How many MAIA options does Himmelreich hold after this Form 4 transaction?

After this grant, Himmelreich is reported to hold 30,000 stock options directly. These options are each exercisable into one share of MAIA common stock, subject to the vesting schedule and the April 10, 2036 expiration date.

Are the MAIA options grant to Himmelreich a market buy or a compensation award?

The transaction is a grant or award acquisition of stock options, not an open-market share purchase. It was made under MAIA Biotechnology’s 2021 Equity Incentive Plan as part of Himmelreich’s compensation, with no cash paid per option at grant.